Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

Share Price is delayed by 15 minutes
Get Live Data
20.75    0.00 (0.00%)
Bid:
20.50
Ask:
21.00
Spread: 0.50 (2.439%)
Market Cap: £215.34m
SCLP Live PriceLast checked at - London Stock Exchange

Intraday Scancell Holdings Share Chart

Holding(s) in Company

18 Jun 2019 09:16

RNS Number : 5998C
Scancell Holdings Plc
18 June 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

SCANCELL HOLDINGS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Seneca Growth Capital VCT Plc

City and country of registered office (if applicable)

London, England

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

17/06/2019

6. Date on which issuer notified (DD/MM/YYYY):

17/06/2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

2.8%

0

2.80

465,355,867

Position of previous notification (if

applicable)

3.5%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

13,049,730

2.8

SUBTOTAL 8. A

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Seneca Growth Capital VCT Plc

2.8

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London, England

Date of completion

17th June 2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLLIFLTRFITLIA
Date   Source Headline
28th Apr 20267:00 amRNSFDA Fast Track Designation for iSCIB1+
2nd Apr 20267:00 amRNSScancell announces CFO transition
29th Jan 20267:00 amRNSHalf-year Financial Report
26th Jan 20267:00 amRNSFDA clearance of IND application for iSCIB1+
22nd Jan 20267:00 amRNSNotice of Results
9th Dec 20257:00 amRNSContinued improvement in PFS with iSCIB1+
7th Nov 20257:00 amRNSResearch Update
30th Oct 20253:30 pmRNSResult of AGM
3rd Oct 20257:00 amRNSNotice of AGM
16th Sep 20257:00 amRNSDirector Dealing
11th Sep 20257:00 amRNSFinal Results
4th Sep 20257:00 amRNSNotice of Results
8th Aug 202512:31 pmRNSDirector Dealing
4th Aug 202510:23 amRNSDirector/PDMR Shareholding
22nd Jul 20257:00 amRNSStrong Phase 2 data on iSCIB1+ in Melanoma
16th Jul 20257:00 amRNSShare Option Exercise
25th Jun 20257:00 amRNSScancell initiates new arm in SCOPE Phase 2 study
21st May 20257:00 amRNSDirector Dealing
14th Apr 20257:00 amRNSPartnership with NHS Cancer Vaccine Launch Pad
1st Apr 20257:00 amRNSScancell to present at 2025 AACR Annual Meeting
20th Feb 20257:00 amRNSIssue of share options
17th Feb 20257:00 amRNSScancell presenting at AACR IO conference
30th Jan 20257:00 amRNSInterim Results
23rd Jan 20257:00 amRNSNotice of Interim Results
9th Jan 20257:00 amRNSModi-1 Vaccine Achieves Early Clinical Validation
9th Dec 202411:41 amRNSResult of Retail Offer and Total Voting Rights
5th Dec 202412:39 pmRNSResult of Placing and Subscription
4th Dec 20246:03 pmRNSRetail Offer for up to £1 million
4th Dec 20245:59 pmRNSProposed fundraise in excess of £8.5 million
4th Dec 20247:00 amRNSSecond Commercial License Agreement with Genmab
18th Nov 20247:00 amRNSPositive data from Phase 2 SCOPE trial with SCIB1
25th Oct 20243:26 pmRNSResult of Annual General Meeting
24th Oct 20247:00 amRNSHolding(s) in Company
22nd Oct 20247:00 amRNSScancell Appoints Dr Phil L’Huillier as CEO
1st Oct 20247:00 amRNSNotice of AGM
24th Sep 20247:00 amRNSResults Year Ended 30 April 2024
18th Sep 20247:00 amRNSNotice of Final Results
17th Sep 20247:00 amRNSStrategic Partnership with PharmaJet
2nd Sep 20247:00 amRNSScancell to attend upcoming conferences
30th Jul 20247:17 amRNSScancell Appoints Dr Nermeen Varawalla as CMO
30th Jul 20247:00 amRNSScancell Appoints Dr Nermeen Varawalla as CMO
24th Jul 20247:00 amRNSUpdate from iSCIB1+ Clinical Advisory Meeting
10th Jul 20247:00 amRNSAppointment of Dr Florian Reinaud to the Board
2nd Jul 20247:00 amRNSExtension of Convertible Loan Notes
1st Jul 20247:00 amRNSBlock Listing Return and Total Voting Rights
21st Jun 20247:00 amRNSChange of Nominated Advisor
12th Jun 20247:32 amRNSAgreement with major biotech
31st May 20247:00 amRNSScancell to attend upcoming conferences
30th May 20247:00 amRNSUpdate on ModiFY trial
24th May 20247:00 amRNSScancell to present at ASCO Annual Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.